Free Trial

Enlivex Therapeutics (ENLV) Competitors

Enlivex Therapeutics logo
$0.98 0.00 (-0.26%)
As of 05/22/2025 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ENLV vs. XBIT, ENTX, IVVD, CHRS, CRDL, IMUX, ZNTL, KYTX, ORMP, and ANIX

Should you be buying Enlivex Therapeutics stock or one of its competitors? The main competitors of Enlivex Therapeutics include XBiotech (XBIT), Entera Bio (ENTX), Invivyd (IVVD), Coherus BioSciences (CHRS), Cardiol Therapeutics (CRDL), Immunic (IMUX), Zentalis Pharmaceuticals (ZNTL), Kyverna Therapeutics (KYTX), Oramed Pharmaceuticals (ORMP), and Anixa Biosciences (ANIX). These companies are all part of the "pharmaceutical products" industry.

Enlivex Therapeutics vs.

XBiotech (NASDAQ:XBIT) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, community ranking, institutional ownership and profitability.

Enlivex Therapeutics has a consensus target price of $10.00, indicating a potential upside of 939.39%. Given Enlivex Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Enlivex Therapeutics is more favorable than XBiotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XBiotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Enlivex Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.33

XBiotech received 257 more outperform votes than Enlivex Therapeutics when rated by MarketBeat users. However, 81.08% of users gave Enlivex Therapeutics an outperform vote while only 69.82% of users gave XBiotech an outperform vote.

CompanyUnderperformOutperform
XBiotechOutperform Votes
317
69.82%
Underperform Votes
137
30.18%
Enlivex TherapeuticsOutperform Votes
60
81.08%
Underperform Votes
14
18.92%

55.7% of XBiotech shares are held by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are held by institutional investors. 33.1% of XBiotech shares are held by company insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

XBiotech's return on equity of -15.99% beat Enlivex Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
XBiotechN/A -15.99% -14.85%
Enlivex Therapeutics N/A -67.57%-58.45%

XBiotech has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500.

In the previous week, XBiotech and XBiotech both had 1 articles in the media. XBiotech's average media sentiment score of 0.00 equaled Enlivex Therapeutics'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
XBiotech
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Enlivex Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

XBiotech has higher revenue and earnings than Enlivex Therapeutics. XBiotech is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XBiotech$4.01M21.59-$24.56M-$1.29-2.20
Enlivex TherapeuticsN/AN/A-$29.07M-$0.73-1.32

Summary

XBiotech beats Enlivex Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Enlivex Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ENLV vs. The Competition

MetricEnlivex TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$22.76M$6.47B$5.33B$8.39B
Dividend YieldN/A2.64%5.21%4.11%
P/E Ratio-0.989.0626.7919.70
Price / SalesN/A259.83393.69121.79
Price / CashN/A65.8538.2534.62
Price / Book0.596.456.774.50
Net Income-$29.07M$143.98M$3.23B$248.22M
7 Day Performance-3.79%0.38%0.42%-0.80%
1 Month Performance4.58%2.14%9.06%11.52%
1 Year Performance-29.26%-0.33%18.55%8.99%

Enlivex Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ENLV
Enlivex Therapeutics
2.0487 of 5 stars
$0.96
-1.8%
$10.00
+939.4%
-33.2%$22.76MN/A-0.9870Positive News
XBIT
XBiotech
0.1783 of 5 stars
$3.07
+1.0%
N/A-66.9%$93.60M$4.01M-2.84100
ENTX
Entera Bio
1.7975 of 5 stars
$2.05
+1.0%
$10.00
+387.8%
-17.3%$93.18M$223,000.00-7.8820News Coverage
IVVD
Invivyd
2.8953 of 5 stars
$0.78
-0.1%
$7.52
+869.1%
-64.8%$93.04M$25.38M-0.40100
CHRS
Coherus BioSciences
3.6782 of 5 stars
$0.80
+5.1%
$4.68
+485.4%
-63.3%$92.75M$272.25M-10.00330Analyst Downgrade
CRDL
Cardiol Therapeutics
1.5225 of 5 stars
$1.12
+0.9%
$8.40
+650.0%
-50.9%$92.52MN/A-2.8720
IMUX
Immunic
2.3806 of 5 stars
$0.96
0.0%
$13.20
+1,274.0%
-27.5%$92.05MN/A-0.7870
ZNTL
Zentalis Pharmaceuticals
1.7561 of 5 stars
$1.25
-0.8%
$8.24
+559.6%
-89.6%$90.66M$26.87M-0.50160
KYTX
Kyverna Therapeutics
2.1767 of 5 stars
$2.07
-10.8%
$18.33
+785.7%
-81.5%$89.46M$7.03M-0.6196News Coverage
Analyst Revision
Gap Down
ORMP
Oramed Pharmaceuticals
1.7976 of 5 stars
$2.14
-0.5%
N/A-6.5%$87.42M$1.34M19.4510
ANIX
Anixa Biosciences
1.7098 of 5 stars
$2.70
+1.9%
$9.00
+233.3%
+0.0%$86.93M$210,000.00-6.925

Related Companies and Tools


This page (NASDAQ:ENLV) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners